Effect of Circulating Plasma Cells on the Prognosis of Patients with Multiple Myeloma.
10.19746/j.cnki.issn.1009-2137.2023.06.026
- Author:
Fei LI
1
;
Yu-Juan GAO
1
;
Shan-Shan LI
1
;
Yuan-Yuan XI
1
;
Xue-Wei YANG
1
;
Yan-Hua SU
2
Author Information
1. Department of Hematology， The first Affiliated Hospital of Harbin Medical University， Harbin 150007， Heilongjiang Province， China.
2. Department of Hematology， The first Affiliated Hospital of Harbin Medical University， Harbin 150007， Heilongjiang Province， China,E-mail: suyanhua163@163.com.
- Publication Type:Journal Article
- Keywords:
circulating plasma cells;
multiple myeloma;
plasma cell leukemia;
prognostic factors
- MeSH:
Humans;
Multiple Myeloma/pathology*;
Plasma Cells/pathology*;
Retrospective Studies;
Prognosis;
Leukemia, Plasma Cell/diagnosis*
- From:
Journal of Experimental Hematology
2023;31(6):1771-1779
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:to analyze the effect of circulating plasma cells(CPC) on the prognosis of patients with multiple myeloma(MM) in the era of new drugs, and to explore the new definition standard of primary plasma cell leukemia(pPCL).
METHODS:The clinical data of 321 patients with newly diagnosed MM and 21 patients with pPCL admitted to our hospital from January 2014 to May 2022 were retrospectively analyzed. According to the proportion of CPC in peripheral blood smears, all patients were divided into 4 groups: CPC 0% group(211 cases), CPC 1%-4% group(69 cases), CPC 5%-19% group(41 cases) and CPC≥20% group(21 cases). The clinical features of patients in each group were compared and the prognosis fators was analyzed.
RESULTS:The median OS of the four groups were 44.5,21.3,24.6 and 12.8 months, respectively. Among them, 295 patients(86.3%) were treated with new drugs, and the median OS of the four groups were not reached, 26.7, 24.6 and 14.9 months, respectively. As the survival curves of CPC 5%-19% group and CPC≥20% group were similar, the patients were divided into CPC<5% group and CPC≥5% group, the median OS of CPC<5% group was better than that in CPC≥5% (43.5 vs 22.3 months, P<0.001). In addition, the median OS of patients in the CPC 1%-4% group was also significantly lower than that in the CPC 0% group and similar to that in the CPC≥5% group. Multivariate analysis showed that 1%-4% CPC was an independent risk factor for the OS of patients with CPC<5%. The patients with CPC<5% were stratified by R-ISS staging, and the OS of R-ISS stage Ⅰ or stage Ⅱ with 1%-4% CPC was similar to that of R-ISS stage Ⅲ. The newly defined pPCL patients showed increased tumor load and obvious invasive characteristics. Multivariate analysis showed no independent prognostic factors for pPCL, and high-risk cytogenetic abnormalities(HRCA) had no significant effect on the prognosis.
CONCLUSION:The validity of IMWG's new pPCL definition standard was verified, and it was found that the survival of MM with 1%-4% CPC also is poor and the prognosis is very close to pPCL. In addition, the newly defined pPCL has unique clinical and biological characteristics.
